NeurAxis, Inc. (NYSE American: NRXS) is a commercial-stage medical technology company focused on developing and commercializing neuromodulation therapies to address chronic and debilitating gastrointestinal (GI) conditions in children and adults. The company's core proprietary technology is Percutaneous Electrical Nerve Field Stimulation (PENFS), commercialized under the brand name IB-Stim. IB-Stim is a non-surgical, non-drug device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear to regulate pain signaling. It is the first and only FDA-cleared treatment recommended in clinical guidelines for functional abdominal pain associated with irritable bowel syndrome (IBS) in pediatric patients aged 8 to 21. NeurAxis is actively expanding its clinical indications and commercial footprint to address a massive serviceable market estimated at $5 billion for pediatrics and $12 billion for adults.

Research as of 20 Jun 2026